Nab-paclitaxel in Combination with Gemcitabine for Resected Pancreatic Ductal Adenocarcinoma – Adjuvant Therapy

Paclitaxel formulated as albumin bound nanoparticles (Nab-paclitaxel) in combination with gemcitabine is being developed as a treatment option for patients with pancreatic cancer who have undergone surgery to increase the chances of being cured (‘adjuvant therapy’). Both drugs are chemotherapies already being used to treat metastatic pancreatic cancer and other types of cancers and are administered by injection.